JSC Grindeks informs on its investment of 1.6 million lats in the Quality control laboratory, out of which 1.33 million lats will be invested in the construction, but more than 270 thousand lats – in the modern quality control equipment. The project is being carried out to increase the capacity of Microbiology laboratory, which is a unit of Quality control laboratory, and to adapt new pharmaceutical requirements.
The new laboratory will perform pharmaceutical analyses, development and validation of analytical methods. All activities in the laboratory will conform to principles of Good manufacturing Practice (GMP), ISO 9001 and ISO 14001.
By expanding opportunities of quality control Grindeks will provide analytical servicesfor Latvia’s and foreign companies and perform analyses of pharmaceutical products – final dosage forms (tablets, capsules, ointments, gels, syrups,solutions for injections), API’s, as well as the analyses of technological experiments and cleaning validation. The company will perform batch release of pharmaceutical products for EU and CIS countries.
Dr.chem Juris Hmeļņickis, Quality director at JSC Grindeks: „The quality requirements in the pharmaceutical industry and the area of Good Manufacturing Practice increase every year. Producing medications and recognizing our important mission of caring for people’s health, Grindeks constantly improves the performance in quality field. This project will strengthen Grindeks positions and increase our competitiveness. In addition, it will open up opportunities to provide analytical services to other companies in Latvian and abroad.”
Laboratory project is being implemented in several stages. The project is expected to becompleted in May, 2014.
According to the project Microbiology laboratory area will be 250m², but the Quality control laboratory will have a total area of 700m ². The new laboratory will be installed in modern automatic control system that regulates the microclimateand engineering systems, as well as saving energy resources.